Overview

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate